6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

March 31, 2008

Commission File Number 001-14956

BIOVAIL CORPORATION

(Translation of Registrant’s name into English)

7150 Mississauga Road, Mississauga, Ontario, CANADA, L5N 8M5

(Address of principal executive office and zip code)

Registrant’s telephone number, including area code: (905) 286-3000

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x                        Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1).

Yes o                       No x

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7).

Yes o                        No x

Indicate by check mark whether by furnishing the information contained in this form the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g 3-2(b) under the Securities Exchange Act of 1934.

Yes o                       No x

BIOVAIL CORPORATION

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the registration statements on Form S-8 (Registration Nos. 333-92229 and 333-138697) of Biovail Corporation.

INDEX

Exhibit 99.1 News Release dated March 28, 2008 – Biovail Announces Resignation Of Director Jamie Sokalsky

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Biovail Corporation
Date: March 31, 2008	By:	/ s / Jennifer Tindale
		Jennifer Tindale
		Vice President &
		Associate General Counsel

i

EX-99.1

Exhibit 99.1

CONTACT: Nelson F. Isabel

Vice-President, Investor Relations and Corporate Communications

(905) 286-3000

For Immediate Release:

BIOVAIL ANNOUNCES RESIGNATION OF DIRECTOR JAMIE SOKALSKY

Toronto, Canada, March 28, 2008 – Biovail Corporation (NYSE, TSX: BVF) today announced that Jamie Sokalsky has tendered his resignation  from the Company’s Board of Directors. Mr. Sokalsky is Executive Vice President and Chief Financial Officer of Barrick Gold Corporation, where the Chief Executive Officer has taken a leave of absence due to a serious medical condition. As a result, Mr. Sokalsky will focus exclusively on his primary responsibilities at Barrick..

“In his time on our Board, Jamie Sokalsky has made an outstanding contribution to the governance and development of Biovail,” said Dr. Douglas Squires, Interim Chairman of the Board and Chief Executive Officer. “We will miss Jamie’s counsel going forward but understand the circumstances and respect his decision.”

“I have enjoyed my involvement with Biovail and my interaction with fellow directors and management and wish the Company all the best in the future,” said Mr. Sokalsky.

The Compensation, Nominating and Governance Committee of the Board of Directors has begun a search for a replacement for Mr. Sokalsky as part of its continuing efforts on behalf of shareholders to add further independent expertise to the Board.

About Biovail Corporation

Biovail Corporation is a specialty pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, and commercialization of pharmaceutical products utilizing

advanced drug-delivery technologies. For more information about Biovail, visit the Company’s Web site at www.biovail.com.

For further information, please contact Nelson F. Isabel at 905-286-3000 or send inquiries to ir@biovail.com.